We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Intestinal Bacteria Trigger Antibody Class Switching

By Biotechdaily staff writers
Posted on 02 Jul 2007
A recent study has shown how the mucosal cells lining the intestinal walls control the population of beneficial bacteria and may guide developers of drugs designed to stop the growth of gastrointestinal pathogens.

Investigators at Weill Cornell Medical College (New York, NY, USA) studied the mechanism that signaled B cells in the intestinal mucosa to switch to production of IgA2 antibodies. More...
This is an important control mechanism, as IgA2 is more resistant to bacterial proteases than is IgA1. The number of bacteria present is linked to the amount of IgA2.

Their report, published in the June 2007 issue of the journal Immunity, explained that high levels of bacteria in the gut stimulated intestinal epithelial cells to start producing a factor called APRIL (a proliferation-inducing ligand). APRIL, a cytokine-signaling chemical, induced the production of IgA2 in nearby B-cells. The epithelial cells further increased APRIL production by activating dendritic cells via thymic stromal lymphopoietin.

"That is a wholly new finding, since most biologists think of epithelial cells as a barrier cell--not as a highly active player in immune function,” said senior author Dr. Andrea Cerutti, associate professor of patholog4y and laboratory medicine at Weill Cornell Medical College. "Armed with this knowledge, perhaps we can harness the mechanisms we have discovered to ward off more dangerous pathogens that use mucosal surfaces as their point of entry into the body -viruses such as HIV, or Rotavirus, the diarrhea pathogen that kills millions of children in poor countries each year. A better understanding of how the body fights off mucosal pathogens helps us immensely when we try and develop vaccines that target these areas.”


Related Links:
Weill Cornell Medical College

New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.